Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Navenibart (STAR-0215) in Hereditary Angioedema
NCT06007677Phase 2Active, not recruiting
- Sponsor
- Astria Therapeutics
- Start
- Sep 2023
- Primary completion
- Mar 2031
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of navenibart in hereditary angioedema (HAE), sponsored by Astria Therapeutics. Started Sep 2023; status: active, not recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06007677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007677.